The role of myeloid-derived suppressor cells in hematologic malignancies
Emine Gulsen Gunes1,2, Steven T Rosen1,2, Christiane Querfeld2,3
1Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Medical Center.
Purpose Of Review:
This article focuses on the immunosuppressive impact of myeloid-derived suppressor cells (MDSCs) and the potential clinical implications in hematological malignancies.
Recent Findings:
MDSCs play a critical role in the regulation of the immune response in cancer. They inhibit activation of adaptive immune response and as a result foster the growth of the malignancy. Recent studies have shown that MDSCs serve as prognostic biomarkers and as targets for cancer immunotherapy. Preclinical and clinical studies have identified new approaches to deplete MDSC populations and inhibit MDSC function with combination immunomodulatory therapies including chemotherapeutic agents with immune checkpoint-directed treatment.
Summary:
A broad spectrum of publications indicate that direct targeting of MDSCs may abrogate their protumorigenic impact within the tumor microenvironment through activation of the adaptive immune response.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
Multipotency of Hematopoietic Stem Cells
Mesenchymal Stem Cells
Abnormal Proliferation
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...


